Tacaciclib (XL102, AUR102) is a potent, orally bioavailable, highly selective covalent CDK7 inhibitor.
Tacaciclib (XL102, AUR102) selectively targets, covalently binds to and inhibits the activity of CDK7, thereby inhibiting CDK7-mediated signaling.
Tacaciclib (XL102, AUR102) prevents phosphorylation of the carboxy-terminal domain (CTD) of RNA polymerase II, thereby preventing transcription of important cancer-promoting genes.
